EP Patent

EP4523749A2 — Variants of c-type natriuretic peptide

Assigned to Biomarin Pharmaceutical Inc · Expires 2025-03-19 · 1y expired

What this patent protects

The invention provides a C-type natriuretic peptide (CNP) variant, wherein the amino acid sequence of the CNP variant is LQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-38), a conjugate comprising the CNP variant and a hydrophilic polymer, and their use for the treatment of a bone-re…

USPTO Abstract

The invention provides a C-type natriuretic peptide (CNP) variant, wherein the amino acid sequence of the CNP variant is LQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-38), a conjugate comprising the CNP variant and a hydrophilic polymer, and their use for the treatment of a bone-related disorder or skeletal dysplasia.

Drugs covered by this patent

Patent Metadata

Patent number
EP4523749A2
Jurisdiction
EP
Classification
—
Expires
2025-03-19
Drug substance claim
No
Drug product claim
No
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.